Wibawa, I Made Dwi Surya
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

POST-EVACUATION OF SILICONE OIL COMPLICATIONS IN RHEGMATOGENOUS RETINAL DETACHMENT PATIENTS WHO UNDERWENT PARS PLANA VITRECTOMY AT TERTIARY HOSPITAL IN BALI, INDONESIA Andayani, Ari; Wibawa, I Made Dwi Surya; Suryathi, Ni Made Ari; Triningrat, Anak Agung Mas Putrawati; Manuaba, Ida Bagus Putra
International Journal of Retina Vol 6 No 1 (2023): International Journal of Retina (IJRetina) - INAVRS
Publisher : Indonesian Vitreoretinal Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35479/ijretina.2023.vol006.iss001.221

Abstract

Introduction: Pars plana vitrectomy with silicone oil injection has become a standard procedure to treat retinal detachment with complex cases. Considerations related to the use of silicone oil are the need for additional surgical procedures to remove silicone oil after the retinal condition is declared stable or because emulsification of silicone oil has occurred. Methods: An analytical observational study with a cross-sectional approach. Data were collected retrospectively by collecting medical records of patients who underwent silicone oil evacuation in 2021. Result: The research subjects were 23 people, where 52.2% of the subjects were women with a median age of 51 years. Most of the subjects (65.2%) had no complications, with the most complications occurring were secondary glaucoma (13%) and redetached retina (13%). There was no statistically significant difference between visual acuity before and after the evacuation of silicone oil with a P value of 0.202 and there was no statistically significant difference between IOP before and after evacuation of silicone oil with a P value of 0.132. Conclusion: Evacuation of silicone oil is a follow-up action after PPV with SO tamponade. Complications which may arise are detach dan glaucoma. There was no significant difference in visual acuity and IOP before and after SO evacuation.
Efektivitas Suplementasi Lutein dan Zeaxanthin terhadap Perkembangan Atrofi Geografis dan Ketajaman Penglihatan pada Degenerasi Makula Terkait Usia: Tinjauan Sistematis Berdasarkan Uji Klinis: Tinjauan Sistematik Kesumaputri, Komang Diah Kurnia; Dwipayani, Ni Made; Wibawa, I Made Dwi Surya; Agrasidi, Putu Anindya; -, Felicia
Cermin Dunia Kedokteran Vol 53 No 05 (2026): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v53i05.2155

Abstract

Introduction: Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can cause severe central vision loss if its progression extends to the foveal area. Currently, therapeutic options for GA remain limited, with safety profiles requiring further evaluation. Lutein and zeaxanthin, as the main components of the Age-Related Eye Disease Study (AREDS2) formula, have become the focus of current research. Both are antioxidants concentrated in the macula, which exert protective effects on retinal structures and reduce oxidative stress. This systematic review aims to evaluate the effectiveness of oral lutein and zeaxanthin supplementation on GA progression and visual acuity in AMD patients. Methods: Literature searches were conducted across four biomedical databases based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. A total of four studies met the inclusion criteria and were analyzed qualitatively. Results: The analysis showed that oral supplementation of lutein (10 mg/day) and zeaxanthin (2 mg/day) may reduce the progression of non-central GA and stabilize or improve visual acuity in patients with AMD. Lutein at doses of 10 mg and 20 mg demonstrated similar effectiveness in improving visual acuity through an increase in macular pigment optical density (MPOD). Conclusion: Based on the findings of this systematic review, oral supplementation with lutein (10 mg/day) and zeaxanthin (2 mg/day), as incorporated in the AREDS2 formulation, appears to slow the progression of non-central GA and preserve foveal integrity (foveal sparing). Further long-term studies are required to confirm the clinical benefits and long-term safety.